Creativity can flourish for many people after an Alzheimer’s diagnosis, like Rebecca Chopp learning how to paint and Reda Harrison rediscovering quilting. For award-winning…
When you’re concerned about Alzheimer’s disease, it can be difficult to determine what symptoms are normal aging and what is cause for concern. Betsy…
What would you do if, after years of living with Alzheimer’s disease, you found out you were misdiagnosed? Retired neuroscience nurse practitioner Doreen Monks…
For 25 years, Mark Sennet worked as a photojournalist and celebrity photographer for Life and People Magazine. He has photographed royals, presidents, sports legends,…
In February, Biogen announced it was pulling Aduhelm off the market. The company will continue supplying the drug until November but stopped providing it…
When Reda Harrison came back from vacation to her University of Kentucky hospital plastic surgery coordinator job at home in Lexington, Kentucky, something was…
It can be challenging to find information about Alzheimer’s clinical trials, let alone find trial participants’ first-hand accounts of their experiences. People living with…
When Rev. Dr. Cynthia Huling Hummel was first diagnosed with amnestic cognitive impairment (aMCI) and had to leave her role as a pastor in…
When Doreen Monks first started showing symptoms of Alzheimer’s disease, she was working as a neuroscience nurse practitioner. While she was having problems managing…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. An Alzheimer’s diagnosis is often talked about…
High-tech treatments for neurodegenerative diseases aren’t so far off. In fact, some patients already have brain implants that help address their symptoms by sending…
Before her diagnosis of mild cognitive impairment and early-stage Alzheimer’s in 2019, Rebecca Chopp was a widely published author, editor, and academic, serving as…
Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
I’ve always been a bit of a technology geek. I still have a few memories of sitting at my desk at the ACLU’s Washington…